SKP2 and cancer: For CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD, HNSCC (head and neck squamous cell carcinoma), kidney cancer, LIHC, LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), STAD (stomach adenocarcinoma), and UCEC, in comparison to normal tissues, the staining intensity of anti-SKP2 antibody was significantly stronger in cancer tissues (Fig. 3A), while the converse trend was investigated in THCA (Fig. 3A).